NutriBand Secures $5M Non-Convertible Credit Line Extension for Fentanyl Patch Commercialization
Summary
NutriBand Inc. secured a $5 million non-convertible credit line extension, providing vital funding for the FDA approval and commercialization of its lead abuse-deterrent fentanyl patch.
Key Events
-
Credit Line Extension Formalized
NutriBand Inc. entered into an amended three-year $5,000,000 credit line facility on June 1, 2026, replacing a previous facility that was scheduled to expire on July 13, 2026. The new facility matures on July 1, 2029.
-
Non-Dilutive Financing
The credit line bears interest at 7% per annum and does not permit conversion by the lender of outstanding amounts into common stock, avoiding direct equity dilution for existing shareholders.
-
Strategic Funding for Lead Product
Proceeds from the credit line are specifically designated to finance the FDA approval process and commercial scale manufacturing for the company's patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.
-
Addresses Financial Concerns
This formal agreement provides crucial capital, extending the company's financial runway and addressing 'going concern doubts' that were noted in the recent Q1 2026 10-Q filing.
Analysis
NutriBand Inc. has formalized a three-year extension of its $5 million credit line, crucial for funding the FDA approval process and commercial manufacturing of its AVERSA™ Fentanyl patch. This non-convertible debt facility provides essential capital without immediate shareholder dilution, addressing prior financial concerns and extending the company's operational runway through a critical development phase. This follows the company's Q1 2026 10-Q filing on June 11, 2026, which first mentioned the credit line extension and its role in alleviating going concern doubts.
At the time of this filing, NTRB was trading at $3.24 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $35.3M. The 52-week trading range was $2.90 to $11.68. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.